The Regulatory Landscape of Psychedelic Medicine in New Zealand

June 23rd, 2026

In June 2025, New Zealand’s Ministry of Health quietly marked a historic milestone: a Christchurch psychiatrist received the country’s first approval to prescribe medicinal psilocybin outside of a research setting. This long overdue moment marked Aotearoa’s entry into a small but fast-growing group of countries where psychedelic-assisted therapy is now a clinical reality.

If you work in mental health, medicine, or allied health, understanding the current regulatory environment is essential. Here’s where things stand.

How Psilocybin Is Classified in New Zealand

Psilocybin remains a Class A controlled drug under the Misuse of Drugs Act 1975, the most restrictive classification in New Zealand’s drug scheduling system. It also doesn’t have any approved medicines registered with Medsafe, which means that it hasn’t been formally assessed for safety and efficacy through the standard medicine approval process.

This classification hasn’t changed. What has changed is the pathway to legal clinical use.

The Regulatory Pathway: Regulation 22

The legal mechanism that enables psilocybin prescribing is Regulation 22 of the Misuse of Drugs Regulations 1977. This provision allows the Director-General of Health to grant individual practitioners authority to prescribe, supply, and administer certain controlled drugs for defined clinical purposes, all outside of research settings.

In practice, this functions as a Ministerial approval scheme. It’s not a blanket rescheduling of the substance, and it’s not a clinical trials requirement. Instead, each practitioner must apply individually to the Minister for approval. However, responsibility for that approval has been delegated to the medicines regulator MedSafe. 

On 24 July 2025, Medsafe published its official guidelines for these applications, the framework that will govern how the field develops in New Zealand for the foreseeable future.

What the MedSafe Guidelines Require

Medsafe assesses applications across four domains:

  1. The Medical Practitioner: Applicants must be registered with the Medical Council of New Zealand and hold a current Annual Practising Certificate (APC) with an appropriate vocational scope. Medsafe also looks for demonstrated clinical experience, especially prior involvement in psychedelic research settings, or a working relationship with established practitioners.
  2. The Product: The product must be pharmaceutical-grade. Raw mushrooms and non-pharmaceutical extracts are explicitly excluded. Because no approved psilocybin products exist in New Zealand, applicants are responsible for sourcing the medicine, which may require a Licence to Import Controlled Drugs if sourcing from overseas.
  3. The Treatment Protocol: This is the most detailed requirement. The protocol must specify the indication, participant selection criteria, consent processes, medication interactions, dosing sessions, rescue medications, efficacy assessment, outcome measures, follow-up procedures, and the clinical therapists who will provide support. The treatment must be conducted in an appropriate supervised environment.
  4. Scientific Peer Review: Applications must include independent, scientific peer review of the proposed treatment protocol. This peer review should be in place before the application is submitted, and practitioners should maintain access to an appropriate professional support network.

What This Means in Practice

New Zealand’s approach bears the closest resemblance to Australia’s Authorised Prescriber (AP) pathway, which has been in place since July 2023. Both countries require individual practitioner approval, pharmaceutical-grade product, and documented clinical protocols rather than simply rescheduling the substance.

Until the first approvals, psilocybin was only accessible here through research; Regulation 22 now lets patients access psilocybin-assisted therapy in real-world clinical settings where a qualified, approved practitioner is involved in their care.

As of early 2026, the number of approved practitioners in New Zealand remains very small. However, the Medsafe framework has created a clear, if rigorous, expansion pathway.

What About MDMA?

MDMA-assisted therapy for PTSD is not currently included in the Regulation 22 guidance. A Ministry of Health briefing document noted that no change was considered warranted for MDMA at this stage. This may evolve, but MDMA remains outside the practical scope of the current framework.

However, at the time of writing this blog, there are applications sitting with MedSafe for MDMA-assisted therapy. PsyTrain is supporting some of these applicants with their submissions.

The Road Ahead

New Zealand is now one of a small number of countries (including Australia, Switzerland, parts of the United States, Germany, and the Czech Republic) where formal, structured pathways for medical psychedelic use exist. The field is evolving rapidly, and regulatory guidance will continue to develop as more practitioners build experience and evidence accumulates.

For clinicians thinking about this space, the message is clear: preparation now matters. The Medsafe guidelines reward practitioners who arrive with clinical experience, peer networks, and documented protocols, not practitioners who arrive with interest alone.

PsyTrain NZ is here to support that journey. Our New Zealand-focused training offerings are designed to meet practitioners where they are and take them where the field is going. Join our mailing list to stay updated on forthcoming trainings.

All Posts